Georgesen Corey, Lipner Shari R
Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
J Cosmet Dermatol. 2017 Jun;16(2):174-179. doi: 10.1111/jocd.12347. Epub 2017 Apr 21.
ATX-101 (deoxycholic acid) is the first pharmaceutical therapy approved by the FDA for the reduction in submental fat. Deoxycholic acid is an endogenous secondary bile acid that normally solubilizes dietary fat, contributing to its breakdown and absorption within the gut. This article reviews the identification of deoxycholic acid as a lipolytic agent, and the mechanism of action, pharmacokinetics, and pharmacodynamics of ATX-101. In addition to phase I/II trials, four Phase III clinical trials have evaluated safety and efficacy of ATX-101. These studies helped establish the appropriate dosage, administration techniques, warnings, and side effects of ATX-101. ATX-101 is effective in treating submental fat. Adverse events, although common, are mild and transient.
ATX-101（脱氧胆酸）是美国食品药品监督管理局（FDA）批准的首个用于减少颏下脂肪的药物疗法。脱氧胆酸是一种内源性次级胆汁酸，通常可溶解膳食脂肪，有助于其在肠道内的分解和吸收。本文综述了脱氧胆酸作为一种脂肪分解剂的发现，以及ATX-101的作用机制、药代动力学和药效学。除了I/II期试验外，四项III期临床试验评估了ATX-101的安全性和有效性。这些研究有助于确定ATX-101的合适剂量、给药技术、注意事项和副作用。ATX-101在治疗颏下脂肪方面有效。不良事件虽然常见，但症状轻微且为一过性。
